Coronary Artery Disease Clinical Trial
— POLARSTAROfficial title:
Clinical Investigation of Intracoronary Cryotherapy Using the CryoTherapy System (CTS) for High-risk Plaque in Patients With Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or Unstable Angina
The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at high-risk of rupture which would cause a major heart attack. The CTS is used to apply local freezing of the lesion using a balloon catheter, controlled by a console that regulates in- and outflow of a cooling agent into the catheter. The treatment is expected to stabilize the lesion, diminishing the risk of rupture. The study will enrol subjects with acute coronary disease who have suitable coronary lesions. Subjects will be followed for 1 year after the CTS treatment. Baseline identification of lesions will be done using Coronary CT-angiography (CCTA), which will be repeated at 3 and 9 months after procedure.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 31, 2025 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is at least 18 years old. 2. Subject has acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria: 1. Non-ST-segment elevation myocardial infarction (NSTEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis 2. Unstable angina 3. Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion. 4. Subject has at least one high-risk plaque meeting the criteria below: 1. Located in a non-culprit vessel, 2. High-risk plaque lesion on CCTA and at least one of the following features: 1. Presence of low-attenuation plaque (HU<50) and/or 2. Positive remodelling (remodelling index >1.1) and/or 3. Napkin ring sign and/or 4. Plaque burden =70% 3. Lesion length = 20 mm. 4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR>0.80 or non-hyperemic pressure ratios (NHPR) >0.89). 5. Reference vessel diameter (RVD) < 3.75 mm and > 2.00 mm in diameter 6. Investigator considers that lesions are accessible. 7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment. 5. Subject is able to provide consent and has signed and dated the informed consent form. Exclusion Criteria: 1. Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP). 2. Subject has ongoing ST-segment elevation myocardial infarction. 3. Subject had a procedural complication during the Acute coronary syndrome (ACS) PCI procedure. 4. Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure. 5. Subject has known reduced Left Ventricular Ejection Fraction < 30%. 6. Subject has known severe valvular heart disease. 7. Subject has known severe renal insufficiency (eGFR <30 ml/min/1.72 m2). 8. Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy < 12 months. 9. Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint. 10. Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device). Angiographic exclusion criteria: 1. Visible distal embolization/no-reflow following culprit lesions PCI. 2. Left main coronary artery disease (visual diameter stenosis > 50%). 3. Stent thrombosis/restenosis as a culprit lesion. 4. CTS lesion involving a bifurcation (defined as lesions involving side branches >2.0 mm). 5. Angiographic or CCTA evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion. 6. Thrombotic lesions 7. Ostial lesions |
Country | Name | City | State |
---|---|---|---|
Georgia | Israeli-Georgian Research Clinic Helsicore | Tbilisi | |
Georgia | Tbilisi Heart Center | Tbilisi | |
Lithuania | Hospital of Lithuanian University of health sciences Kauno Klinikos | Kaunas | |
Lithuania | Vilnius University Hospital Santaros Klinikos | Vilnius |
Lead Sponsor | Collaborator |
---|---|
Cryotherapeutics SA | CoreAalst BV |
Georgia, Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: Rate of Cryotherapy related adverse events | Any cryotherapy procedure related complication defined as coronary artery dissection (angiographic dissection = NHLBI type B), acute vessel closure, life threatening arrythmia, need for bailout stenting, or any Major Adverse Cardia Event (MACE) defined as cardiac death, CTS-treated vessel myocardial infarction, CTS-treated lesion revascularization, rehospitalization for unstable or progressive angina adjudicated to the CTS-treated lesion | 90 days post-procedure | |
Secondary | Safety: Rate of Cryotherapy related events | Any cryotherapy procedure related complication defined as coronary artery dissection (angiographic dissection = NHLBI type B), acute vessel closure, life threatening arrythmia, need for bailout stenting, or any MACE defined as cardiac death, CTS-treated vessel myocardial infarction, CTS-treated lesion revascularization, rehospitalization for unstable or progressive angina adjudicated to the CTS-treated lesion | 1 year post-procedure | |
Secondary | Device success | Number of lesions successfully treated without device deficiency | end of CTS treatment | |
Secondary | CTS procedure success | Number of lesions successfully treated to obtain Thrombolysis in Myocardial Infarction (TIMI) 3 flow | end of CTS treatment | |
Secondary | Imaging: CCTA assessed Minimum lumen area (MLA) | Change in MLA (mm²) compared to baseline | 90 days post-procedure | |
Secondary | Imaging: CCTA assessed Minimum lumen area (MLA) | Change in MLA (mm²) compared to baseline | 9 months post-procedure | |
Secondary | Imaging: CCTA assessed area stenosis | Change in area stenosis % compared to baseline | 3 months post-procedure | |
Secondary | Imaging: CCTA assessed area stenosis | Change in area stenosis % compared to baseline | 9 months post-procedure | |
Secondary | Imaging: CCTA assessed lesion plaque burden | Change in lesion plaque burden % from baseline | 3 months post-procedure | |
Secondary | Imaging: CCTA assessed lesion plaque burden | Change in lesion plaque burden from baseline | 9 months post-procedure | |
Secondary | Imaging: CCTA assessed Total plaque volume | Change in total plaque volume (mm³) from baseline | 3 months post-procedure | |
Secondary | Imaging: CCTA assessed Total plaque volume | Change in total plaque volume(mm³) from baseline | 9 months post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |